Health care giant Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil investigations, the Department of Justice announced Monday.

Allegations relate to the prescription drugs Risperdal, Natrecor, and Invenga. They include fraudulent promotion of drugs for uses not approved by the Food and Drug Administration, and kickbacks to physicians and pharmacists.

The settlement includes $1.72 billion in civil settlements with the federal government and states and $485 million in criminal fines and forfeiture.

"The conduct at issue in this case jeopardized the health and safety of patients and damaged the public trust," Attorney General Eric Holder said. "This multibillion-dollar resolution demonstrates the Justice Department's firm commitment to preventing and combating all forms of health care fraud. And it proves our determination to hold accountable any corporation that breaks the law and enriches its bottom line at the expense of the American people."

The $2.2 billion resolution is one of the biggest health care fraud settlements in American history.